Attenuon, LLC

Dart Neuroscience, (cayman) Ltd.

University of Michigan

Wilson Therapeutics Ab

Amy Lynn Allan

Robert J Ternansky

Andrew P Mazar

Patricia L Gladstone

Laurent Gomez

Tami Jo Marrone

Fernando Donate

Melissa L P Price

Sean M O'Hare

Brian Dyck

Graham Parry

Terence P Keenan

Kiev S Ly

James Breitenbucher

Robert Huerta Lemus

Bryan James Branstetter

Michael I Weinhouse

Marco Peters

Stephanie Hopkins

Won Hyung Yoon

Dimitri Coucouvanis

Steven Pirie-Shepherd

Andrew Mazar

Marian Plunkett

Mellissa L P Price

Sean M O'HARE

Steven Robert Pirie-Shepherd

The invention provides a chemical entity of Formula (I): (I), wherein R, R, R, and R, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors

Described herein are compounds and chemical entities of Formula (I), methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders. 

Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders

The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-&#x3ba;B dysregulation.

Thiotungstate analogues and uses thereof

The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-&#x3ba;B dysregulation and methods of using pharmaceutical compositions of thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-&#x3ba;B dysregulation.

Thiomolybdate analogues and uses thereof

Growing community of inventors

Encinitas, CA, United States of America

Amy Lynn Allan